Literature DB >> 3182080

Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

J Champsi1, D McMahon-Pratt.   

Abstract

Previous passive antibody transfer experiments have indicated that immunity to a 46-kilodalton membrane glycoprotein (M-2) of Leishmania amazonensis may protect against infection with this parasite. In the studies described in this paper, we investigated the ability of the purified M-2 molecule to elicit a protective immune response in conjunction with Freund incomplete and complete adjuvants, saponin, and Corynebacterium parvum. Both relatively susceptible (BALB/c and CBA) and resistant (C57BL/6) strains of mice were examined. C. parvum appeared to be the most effective adjuvant in the three mouse strains tested. The level of protection varied with the mouse strain, although all animals received identical preparations of antigen and adjuvant. Immunization of CBA mice with the M-2 glycoprotein and C. parvum resulted in complete protection against a challenge infection of 10(4) and 10(6) late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms). The level of protection observed is reflected by increased antibody response (immunoglobulins G1 and G2) developed to the M-2 molecule. The relationship of pure T-cell (nonantibody) immunity to this protection remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182080      PMCID: PMC259734          DOI: 10.1128/iai.56.12.3272-3279.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  DISSEMINATED CUTANEOUS LEISHMANIASIS; INNOCULATION TO LABORATORY ANIMALS, ELECTRON MICROSCOPY AND FLUORESCENT ANTIBODIES STUDIES.

Authors:  J CONVIT; F KERDEL-VEGAS
Journal:  Arch Dermatol       Date:  1965-05

2.  B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis.

Authors:  P Scott; P Natovitz; A Sher
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

3.  Leishmania spp.: agar plating as an alternative to limiting dilution and impression smears for the enumeration of viable parasites in tissue.

Authors:  J O Hill; J R Fahey
Journal:  Exp Parasitol       Date:  1987-02       Impact factor: 2.011

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein.

Authors:  L P Kahl; D McMahon-Pratt
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

6.  Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.

Authors:  J Convit; P L Castellanos; A Rondon; M E Pinardi; M Ulrich; M Castes; B Bloom; L Garcia
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

7.  Effect of Corynebacterium parvum on the class and subclass of antibody produced in the response of different strains of mice to sheep erythrocytes.

Authors:  G W Warr; K James
Journal:  Immunology       Date:  1975-03       Impact factor: 7.397

8.  Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis.

Authors:  J J Shaw; R Lainson
Journal:  Trans R Soc Trop Med Hyg       Date:  1975       Impact factor: 2.184

9.  Modulation of the pattern of development of experimental disseminated leishmaniasis by Corynebacterium parvum.

Authors:  J O Hill
Journal:  J Leukoc Biol       Date:  1987-02       Impact factor: 4.962

10.  The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation.

Authors:  V S Sljivić; S R Watson
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

View more
  39 in total

1.  The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection.

Authors:  Dawn M Wetzel; Diane McMahon-Pratt; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

2.  Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis.

Authors:  K L Lohman; P J Langer; D McMahon-Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.

Authors:  Dawn M Wetzel; Emma L Rhodes; Shaoguang Li; Diane McMahon-Pratt; Anthony J Koleske
Journal:  J Cell Sci       Date:  2016-06-29       Impact factor: 5.285

5.  Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.

Authors:  L P Kahl; R Lelchuk; C A Scott; J Beesley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

7.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 10.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.